We are live on ! Find out more
CRXT

Clarus Therapeutics Holdings, Inc. Common Stock
CRXT

Delisted

CRXT was delisted on the 30th of August, 2022.

Back to rankings

0 hedge funds and large institutions have $0 invested in Clarus Therapeutics Holdings, Inc. Common Stock in 2022 Q4 according to their latest regulatory filings, with funds opening new positions, increasing their positions, 0 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 2 → 0 (-2)

100% less capital invested

Capital invested by funds: $5K → $0 (-$5K)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 2

Holders
–
Holders Change
-2
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
-$5K
Name Holding Trade Value Shares
Change 		Change in
Stake
SM
1
Sabby Management
Florida
– -$5K -146,900 Closed

CRXT Hedge Fund Activity: Q4 2022 in Review

0 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Clarus Therapeutics Holdings, Inc. Common Stock (CRXT) for Q4 2022, worth a combined $0 — down 100% from $5K a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of CRXT and 0 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Sabby Management, exiting entirely with an estimated $5K sold.

  • 0 institutional investors held Clarus Therapeutics Holdings, Inc. Common Stock (CRXT) as of Q4 2022, down from 2 in Q3 2022.
  • Funds reported $0 of Clarus Therapeutics Holdings, Inc. Common Stock stock for Q4 2022, down 100% quarter-over-quarter.
  • 0 funds opened new Clarus Therapeutics Holdings, Inc. Common Stock positions in Q4 2022 and 2 closed out, a net change of -2 holders.
  • The largest Clarus Therapeutics Holdings, Inc. Common Stock seller in Q4 2022 was Sabby Management, an estimated $5K sold.

Based on aggregated 13F filings for Q4 2022.